ライフサイエンスコーパス: CV

1 CV is inversely associated with LGE-CMR fibrosis density

2 CV measurements were made using the main anodic peak see

3 CV risk factors are strongly and similarly associated wi

4 Functional sensitivity defined at 15% CV was 1.9 pg/mL.

5 variability of eosinophil-associated IL-16 (CV = 103%).

6 2)t(R) was reduced on average from 8 and 16% CV prealignment to less than 1 and 2% post alignment, re

7 0, 2.116) and 0.245 (95% CI: - 0.697, 1.187) CV deaths per 100,000 people.

8 es obtained the second best performance (R(2)CV-0.97, RMSECV-0.38 mg/g; R(2)P-0.97, RMSEP-0.36 mg/g).

9 e-transect estimates (0.33 whales per km(2), CV = 0.09).

10 d weather conditions (0.13 whales per km(2), CV = 0.38), they fall within an order of magnitude of th

11 llow-up of 3.7 +/- 2.9 years, there were 208 CV or death events.

12 ation, CV) and protein quantification (<7.5% CV) using data from >2000 samples of human cell lines, t

13 We identified 2 940 920 CV-HF and 8 852 066 cancer deaths.

14 e previously reported Khatyrka meteorite - a CV chondrite containing near-identical alloys and the on

15 el ( p < 1 x 10(-5)) on FP/HW Raman yields a CV diagnostic accuracy of 98.23% (111/113), sensitivity

16 Coxsackievirus A10 (CV-A10) is responsible for an escalating number of sever

17 terovirus 71 (EV-71) and coxsackievirus A16 (CV-A16) may account for the different patterns of HFMD t

18 By raising resistant EV-A71, CV-B3, and EV-D68 variants against one of these inhibito

19 in most instances in patients with adequate CV reserve, they can be particularly challenging in high

20 ever, encapsulation of [Au(25)(Cys)(18)] and CV into the polymer activates potent photobactericidal a

21 he association between LGE-CMR intensity and CV with multilevel linear mixed models.

22 rsely associated with both incident MACE and CV readmission (hazard ratio [HR]: 0.76; 95% confidence

23 ine ratio (p = 0.041), average cell size and CV showed a positive correlation with these parameters.

24 lationship among CRS, elevated troponin, and CV events, and a shorter time from CRS onset to tocilizu

25 ratio on 90 kPa substrates exhibited average CVs of 14 +/- 0.6 cm/s, Action Potential Duration (APD)8

26 ties toward next generation of the BCG-based CV healthcare techniques embedded with transparency, int

27 ere higher for patients with higher baseline CV risk.

28 t is important to determine whether baseline CV risk affects the efficacy of RDN.

29 wn to be strongly associated with beneficial CV effects.

30 is to accurately assess the relation between CV and myocardial fibrosis density on late gadolinium-en

31 2c showed induction of proliferation in both CV- and R47H-transgenic mice.

32 peak currents of colorants were obtained by CV and DPV techniques; and as a result, the two linear r

33 M, with a nice analytical reproducibility by CV (coefficient of variance) value of 8.5 +/- 3.1%, and

34 Cardiovascular (CV) disease fatality rates are higher for women compared

35 testing in reducing adverse cardiovascular (CV) outcomes (CV death or myocardial infarction [MI]) am

36 mellitus and atherosclerotic cardiovascular (CV) disease to once-daily ertugliflozin 5 mg, 15 mg, or

37 rtality, and readmission for cardiovascular (CV) causes at 3 years' follow-up.

38 ) mass quantified by MRI for cardiovascular (CV) events in a contemporary, ethnically diverse cohort.

39 tment for patients with high cardiovascular (CV) risk.

40 T2) inhibitors have improved cardiovascular (CV) outcomes.

41 contributed to reductions in cardiovascular (CV) mortality.

42 rvention (PCI) reduced major cardiovascular (CV) events in patients with ST-segment elevation myocard

43 ascularization reduced major cardiovascular (CV) events in patients with ST-segment elevation myocard

44 The taxonomy of cardiovascular (CV) diseases is divided into a broad spectrum of clinica

45 educes the risk of recurrent cardiovascular (CV) events in patients with prior acute coronary syndrom

46 Rates of subsequent cardiovascular (CV) death/HF hospitalization or all-cause mortality duri

47 The primary outcome was cardiovascular (CV) hospitalization or all-cause mortality.

48 Whether cardiovascular (CV) disease risk factors and biomarkers associate differ

49 tibiotic clarithromycin with cardiovascular (CV) events.

50 se in combined 1- and 2-year cardiovascular (CV) death/rehospitalization (all p < 0.002) and all-caus

51 efficacy outcomes were MACE (cardiovascular [CV] death, myocardial infarction, stroke), CV death/HHF,

52 g of a Vigarano-type carbonaceous chondrite (CV) from the oxidized subgroup at a depth where fluid-as

53 ts (age range, 45-84 years) free of clinical CV disease at baseline were enrolled between 2000 and 20

54 ontent, based on the uniformity coefficient (CV).

55 The study compared CV outcomes in patients with diabetes (n = 1,908 [21%])

56 rfusion (CV(2) (Qtotal)) and its components (CV(2) (Qtotal) = CV(2) (Qvgrad) [vertical gradient] + CV

57 h concern, including EV-A71, coxsackievirus (CV)-A24v, and EV-D68.

58 Prior trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors

59 ontinuous variable quantum key distribution (CV-QKD).

60 hanges in ultraviolet (UV) absorbance during CV and identify transient intermediates and product spec

61 The mean CCT, ECD, CV, CA, and hexagonality was 533.80 +/- 33.00 mum, 2732

62 Changes in ECD, CV, and %HEX from baseline to 3 months were compared bet

63 in changes from baseline to month 3 in ECD, CV, or %HEX between either of the netarsudil groups and

64 Mean ECD, CV, and %HEX values were comparable between groups at ba

65 ed no clinically significant effects on ECD, CV, or %HEX when dosed QD or BID for 3 months in eyes wi

66 The ECD, CV, and %HEX were determined using a standardized protoc

67 In this work therefore we embed CV-QKD signals within classical signals and transmit cla

68 timation Stability with Cross Validation (ES-CV), we were able to, without any prior biological knowl

69 We estimated CV from electroanatomic mapping local activation time us

70 The aim of this study was to examine CV risk following prescription of clarithromycin versus

71 oth iris- and scleral-sutured PCIOLs (except CV-8 polytetrafluoroethylene suture) compared with nonsu

72 sk, often elderly patients with pre-existing CV disease.

73 diovascular deaths related to heart failure (CV-HF) and comparison to cancer deaths have not been ful

74 .020) and 3.984 (95% CI: 2.472, 5.496) fewer CV deaths per 100,000 people respectively.

75 l models had comparable performance (10-fold CV R(2) for the PN [BC] models: 0.42 [0.25]) to previous

76 development of the BCG-based approaches for CV health monitoring.

77 outcomes, and have a consistent benefits for CV death/HHF and progression of kidney disease with dapa

78 ative risk reductions with dapagliflozin for CV death/HHF (HR, 0.86, PAD; HR, 0.82, no-PAD; P-interac

79 3 and 2017 to identify location of death for CV-HF and cancer deaths.

80 MACE, 108 died, and 130 were readmitted for CV causes.

81 ths (beta=1.05 [95% CI, 0.97-1.12]) than for CV-HF deaths (beta=0.61 [95% CI, 0.58-0.64]).

82 ndard deviation]) followed over 15 years for CV events, LV mass was derived from cardiac MRI at basel

83 Results from CV tend to be larger than those from DPV.

84 lope had a 2-fold increased hazard of future CV or death event (multivariable-adjusted hazard ratio:

85 thin-subject incremental mean +/- SD glucose CVs of 91.7 +/- 1.9% and 94.2 +/- 2.7%, respectively.

86 respectively) and acceptable for glyoxylate (CV <18.3% and <6.7% for inter- and intraday precision, r

87 radient] + CV(2) (Qzgrad) [axial gradient] + CV(2) (Qr) [residual heterogeneity]) among groups.

88 otal) = CV(2) (Qvgrad) [vertical gradient] + CV(2) (Qzgrad) [axial gradient] + CV(2) (Qr) [residual h

89 living with HIV had a significantly greater CV(2) (Qr)/CV(2) (Qtotal) (0.48 vs. 0.36, P = 0.05) and

90 Within groups, CV declined in a statistically significant fashion from

91 lozin did not significantly reduce first HHF/CV death (hazard ratio [HR], 0.88 [95% CI, 0.75-1.03]).

92 e to first event of HHF and composite of HHF/CV death, overall and stratified by prespecified charact

93 tio, 0.70 [95% CI, 0.56-0.87]) and total HHF/CV death (rate ratio, 0.83 [95% CI, 0.72-0.96]).

94 ze total (first+recurrent) HHF and total HHF/CV death events.

95 e risk for first and total HHF and total HHF/CV death, adding further support for the use of sodium-g

96 cluded limited numbers of patients with high CV risk and chronic kidney disease.

97 ducibility of this MALDI MS method was high (CV < 10%), and results agreed well (83% overlap) with pr

98 nt, with dispersal unit f having the highest CV and dispersal unit a the lowest.

99 In patients with ICM, CV in areas with no visible fibrosis was 0.81 m/s (95% C

100 ctively coupled plasma mass spectrometry (ID-CV-ICP-MS) and laser absorption spectroscopy (LAS).

101 studies help validate the accuracy of the ID-CV-ICP-MS primary method as well as establish the LAS te

102 t tubes to be subsequently analyzed using ID-CV-ICP-MS.

103 ecision was < 5% and inter-assay imprecision CV was < 10% for high (942 pg/mL) and low (38.2 pg/mL) P

104 Accuracy (%bias) and total imprecision (%CV) were within preset acceptance criteria for all analy

105 .800 ng mL(-1) in DPV and 6.048 ng mL(-1) in CV.

106 We examined changes in CV mortality attributed to reductions in emissions from

107 s represented 5.7% of the overall decline in CV mortality.

108 ever, there was no significant difference in CV(2) (Qvgrad)/CV(2) (Qtotal) between smokers living wit

109 strong opposite effects mask differences in CV.

110 tive contribution to observed differences in CV.

111 However, whether the selectivity observed in CV-1 cells also represented CITCO activity in liver cell

112 erties of cardiac NPs and their potential in CV prevention.

113 % with elevated NT-proBNP) with 825 incident CV events over 10-year follow-up.

114 outh disease causing viruses, which includes CV-A10.

115 ultiple electrochemical techniques including CV and electrochemical quartz crystal microbalance (EQCM

116 al dysfunction was associated with increased CV risk in overweight and obese patients.

117 ch 25% increase in normalized LGE intensity, CV decreased by 1.34-fold (95% CI, 1.25-1.43).

118 nstrated in a green monkey kidney cell line, CV-1, in which CITCO displayed >100-fold selectivity for

119 The outer loop CV was the only circuit component that correlated with T

120 LC-MS/MS measurements confirm low CV and hematocrit independence of the sampling system an

121 n [CV] <= 50%) to moderately variable (50% < CV <= 90%).

122 eduction Study [Reduction in Recurrent Major CV Disease Events] (CANTOS); NCT01327846.

123 se, complete revascularization reduced major CV outcomes to a greater extent in patients with stenosi

124 g NEC having more than four-fold higher mean CV than controls.

125 Median CV in patients with ICM and controls was 0.41 m/s and 0.

126 to a depth of ~1 600 proteins with a median CV of 10.9% and correlation coefficient of 0.98.

127 ) at pH 9 to 38.3 (CC mode) and 34.3 mg/min (CV mode) at pH 5 (84-104% in improvement), respectively.

128 creased from 20.8 (CC mode) and 16.8 mg/min (CV mode) at pH 9 to 38.3 (CC mode) and 34.3 mg/min (CV m

129 CV, 78.1%) for aerosol spray, and 6.6 ng/mL (CV, 103.9%) for nonaerosol spray.

130 73.0%) for nonaerosol spray, and 3.3 ng/mL (CV, 47.8%) for pump spray.

131 enzone, the concentrations were 258.1 ng/mL (CV, 53.0%) for lotion and 180.1 ng/mL (CV, 57.3%) for ae

132 g/mL (CV, 53.0%) for lotion and 180.1 ng/mL (CV, 57.3%) for aerosol spray.

133 L (CV, 68.0%) for aerosol spray, 17.9 ng/mL (CV, 61.7%) for nonaerosol spray, and 13.9 ng/mL (CV, 70.

134 homosalate, concentrations were 23.1 ng/mL (CV, 68.0%) for aerosol spray, 17.9 ng/mL (CV, 61.7%) for

135 , 86.5%) for nonaerosol spray and 5.2 ng/mL (CV, 68.2%) for pump spray.

136 61.7%) for nonaerosol spray, and 13.9 ng/mL (CV, 70.2%) for pump spray.

137 ariation [CV], 73.9%) for lotion, 3.5 ng/mL (CV, 70.9%) for aerosol spray, 3.5 ng/mL (CV, 73.0%) for

138 mL (CV, 70.9%) for aerosol spray, 3.5 ng/mL (CV, 73.0%) for nonaerosol spray, and 3.3 ng/mL (CV, 47.8

139 mL (CV, 81.6%) for aerosol spray, 5.8 ng/mL (CV, 77.4%) for nonaerosol spray, and 4.6 ng/mL (CV, 97.6

140 7.8 ng/mL (CV, 87.1%) for lotion, 6.6 ng/mL (CV, 78.1%) for aerosol spray, and 6.6 ng/mL (CV, 103.9%)

141 r octisalate, concentrations were 5.1 ng/mL (CV, 81.6%) for aerosol spray, 5.8 ng/mL (CV, 77.4%) for

142 r octinoxate, concentrations were 7.9 ng/mL (CV, 86.5%) for nonaerosol spray and 5.2 ng/mL (CV, 68.2%

143 ocrylene, the concentrations were 7.8 ng/mL (CV, 87.1%) for lotion, 6.6 ng/mL (CV, 78.1%) for aerosol

144 77.4%) for nonaerosol spray, and 4.6 ng/mL (CV, 97.6%) for pump spray.

145 gated the genetic relationship to CV and non-CV diseases with reported CAD comorbidity.

146 Integration of noninvasive CV maps with electroanatomic mapping during substrate ma

147 was to evaluate sex-specific associations of CV risk factors and biomarkers with incident HF.

148 ale 54% vs. 52%) but had a greater burden of CV comorbidities.

149 hout PAD are at a higher risk of CV death of CV death, HHF, and kidney outcomes, and have a consisten

150 Noninvasive derivation of CV maps from LGE-CMR is feasible.

151 method that provides an accurate estimate of CV as it accounts for the direction of wavefront propaga

152 ined differences in vertex-wise estimates of CV, CT and SA at each vertex, and compared the frequenci

153 ersus <60% on the first coprimary outcome of CV death or new MI and the second co-primary outcome of

154 new MI and the second co-primary outcome of CV death, new MI, or ischemia-driven revascularization w

155 Increases were noted in the proportion of CV-HF deaths in hospice facilities (0.2% to 8.2%; P(tren

156 The proportion of CV-HF deaths occurring in hospice facilities is increasi

157 ilizumab was associated with a lower rate of CV events.

158 h versus without PAD are at a higher risk of CV death of CV death, HHF, and kidney outcomes, and have

159 thout tended to have higher adjusted risk of CV death, myocardial infarction, or stroke (adjusted haz

160 4) and significantly higher adjusted risk of CV death/HHF (adjusted HR, 1.60 [95% CI, 1.21-2.12], P=0

161 tudy, we observed that the increased risk of CV events with clarithromycin compared with amoxicillin

162 tivity had a significantly increased risk of CV hospitalization at 30 days to 1 year compared with he

163 nificantly associated with increased risk of CV hospitalization compared with amoxicillin at both 0-1

164 Because of a wide spectrum of CV observed within the reentrant path during human VT, t

165 We report here structures of CV-A10 mature virus alone and in complex with KRM1 as we

166 A wide range of CVs was observed within the entrance (0.03-0.55 m/s), co

167 ere localized in areas of slow conduction on CV maps.

168 ecukinumab might have a beneficial effect on CV risk by improving the endothelial function of patient

169 d may be a novel diagnostic tool to optimize CV risk stratification in ESRD and other high-risk CV co

170 CHD death (HR: 4.3; 95% CI: 2.5, 7.3), other CV death (HR: 7.5; 95% CI: 4.2, 13.5), and HF (HR: 5.4;

171 ducing adverse cardiovascular (CV) outcomes (CV death or myocardial infarction [MI]) among symptomati

172 OL, 8-0 polypropylene scleral-sutured PCIOL, CV-8 polytetrafluoroethylene, and intrascleral haptic fi

173 he total spatial heterogeneity of perfusion (CV(2) (Qtotal)) and its components (CV(2) (Qtotal) = CV(

174 ation demonstrates good technical precision (CV = 7.7%, n = 45) and accuracy with a mean recovery of

175 .997), accuracy (RE <= +/- 9.1%), precision (CVs <= 7.7%), and extraction recoveries (85.6-109.3%).

176 than amputee subjects in their preferences (CV of 5.6% for amputee subjects, CV of 23% for prostheti

177 Preoperative CV, percent of hexagonal cells, and CCT were similar in

178 A total of 62 of the 64 presidents' CVs were received and assessed (97% response rate).

179 The ACS and ASA presidents' CVs displayed unsurpassed scholastic achievement, and al

180 ACS, ASA, AWS, and SBAS presidents' CVs, at the time of their presidential term, were assess

181 pooled, excluding individuals with prevalent CV disease and those taking antihypertensive medication

182 h HIV had a significantly greater CV(2) (Qr)/CV(2) (Qtotal) (0.48 vs. 0.36, P = 0.05) and reduced CV(

183 total)) and its components (CV(2) (Qtotal) = CV(2) (Qvgrad) [vertical gradient] + CV(2) (Qzgrad) [axi

184 . 0.36, P = 0.05) and reduced CV(2) (Qvgrad)/CV(2) (Qtotal) (0.46 vs. 0.65, P = 0.038).

185 no significant difference in CV(2) (Qvgrad)/CV(2) (Qtotal) between smokers living with and without H

186 Smokers also had a reduced CV(2) (Qvgrad)/CV(2) (Qtotal), however, there was no significant differ

187 esponses against the known spiked-in ratios (CVs < 8% for calibration standards).

188 rae per specimen (0.76 bacilli per reaction; CV%: 0.65-2.44) and 122 M. lepromatosis per specimen (3.

189 sis per specimen (3.05 bacilli per reaction; CV%: 0.84-2.9), respectively.

190 Smokers also had a reduced CV(2) (Qvgrad)/CV(2) (Qtotal), however, there was no sig

191 total) (0.48 vs. 0.36, P = 0.05) and reduced CV(2) (Qvgrad)/CV(2) (Qtotal) (0.46 vs. 0.65, P = 0.038)

192 from areal sources increased carbon-related CV mortality by 0.788 (95% CI: - 0.540, 2.116) and 0.245

193 estimated PM2.5 total- and component-related CV mortality, adjusted for county-level population chara

194 Comprehensive Cancer Network on ICI-related CV toxicities have also been incorporated.

195 al (CI): 5.703, 7.667] fewer sulfate-related CV deaths per 100,000 people.

196 Other relevant CV markers were unchanged.

197 re than 80 polar/ionic metabolites reliably (CV < 30%) detected in a majority (>75%) of samples with

198 nd other proteases and good reproducibility (CV = 0.2-3.6%), establish new performance standards for

199 rders of magnitude and high reproducibility (CV < 20%, n = 3) were demonstrated using standard glycan

200 hibited the most efficient and reproducible (CV = 9%) anti-CRP functionalization, controlled stopped-

201 and invite the application of time-resolved CV-SAXS to reveal interactions that result in efficient

202 k stratification in ESRD and other high-risk CV cohorts.

203 rast variation small-angle X-ray scattering (CV-SAXS) is a powerful tool with the potential to monito

204 ECD), coefficient of variation in cell size (CV), cell area (CA) and percentage of regular hexagonal

205 atio decreased, while the average cell size, CV%, and central corneal thickness increased.

206 ficantly lower, while the average cell size, CV%, and central corneal thickness were determined to be

207 ickness gradient ( P<0.001) exhibited slower CV.

208 have, on average, 1.97- to 2.66-fold slower CV compared with areas without dense scar.

209 ation (CV) R(2) of 0.86, an improved spatial CV R(2) of 0.81, and a lower prediction error.

210 [CV] death, myocardial infarction, stroke), CV death/HHF, and progression of kidney disease.

211 references (CV of 5.6% for amputee subjects, CV of 23% for prosthetist subjects; p = 0.014).

212 rtainty in model prediction was substantial (CV = 28%).

213 nsored graft loss by non-dosed-corrected TAC CV and TAC TTR during the first posttransplant year in a

214 nsored graft loss by non dosed corrected TAC CV and TAC TTR during the first posttransplant year in a

215 The temporal CV R(2) did not improve due to the temporal discontinuit

216 The CV and CA directly correlated with age (r = 0.242, P < 0

217 In contrast, the CV-treated Cu electrode prepared by oxidizing the as-pre

218 hanges in response to the alterations in the CV risk predictors.

219 hylene conversion is further enhanced in the CV-treated Cu electrode.

220 encapsulation of [Au(25)(Cys)(18)] into the CV treated polymer promotes redox reactions through gene

221 Particularly, the main features of the CV of 2:1, 1:2, 3:1, and 1:3 processes (that is, the pea

222 e and in complex with KRM1 as well as of the CV-A10 A-particle.

223 For the first time, we demonstrate that the CV of the outer loop, rather than isthmus, is the princi

224 The % CV (coefficient of variation) values obtained for each a

225 and investigated the genetic relationship to CV and non-CV diseases with reported CAD comorbidity.

226 d matrix in altered and relatively unaltered CV, CM, and CR (Vigarano-type, Mighei-type, and Renazzo-

227 Associations using CV and CAT were similar.

228 3)O(4)/MWCNTs/GCE surface was examined using CV and differential pulse voltammetry (DPV) techniques.

229 BV and Aptima Candida/Trichomonas vaginitis (CV/TV) assays.

230 el with an improved random cross-validation (CV) R(2) of 0.86, an improved spatial CV R(2) of 0.81, a

231 f Ca content in INF (R(2) (cross-validation (CV))-0.99, RMSECV-0.29 mg/g; R(2) (prediction (P))-1, RM

232 UC 0.92) based on standard cross-validation (CV).

233 igher five-fold cross-validation AUC values (CV-AUC) and Leave-One-Chromosome-Out predicted AUC value

234 reliability (ICC >0.75) and low variability (CV <20%) and could detect known IgE-binding epitopes.

235 cat state is used for a continuous-variable (CV) logical qubit captured in a microwave cavity.

236 ding analyte measurement center of variance (CV) from 3 to 6%.

237 model expressing either the common variant (CV) or the R47H variant of TREM2.

238 x and QT interval the Coefficient Variation (CV) should be greater than or equal to 0.1012, 0.083, 0.

239 00012) in the mean coefficient of variation (CV) between the two groups with infants developing NEC h

240 The coefficient of variation (CV) for intra-assay imprecision was < 5% and inter-assay

241 RI was high with a coefficient of variation (CV) of 1.84 +/- 1.13% across both sites.

242 nd study-wise mean coefficient of variation (CV) of replicate measures (from 1.6% to 14.9%; p < 0.001

243 iance (ANOVA), and coefficient of variation (CV) were used for analysis.

244 relation (ICC) and coefficient of variation (CV) were used for the reliability assessment.

245 and reproducible (coefficient of variation (CV)) < 25%, n = 6) quantitation of N-glycans within 2 or

246 ty was assessed as coefficient of variation (CV), and Pearson's correlation analysis was conducted.

247 um from minimally (coefficient of variation [CV] <= 50%) to moderately variable (50% < CV <= 90%).

248 te and glycolate (coefficients of variation [CV] were <6.3% and <4.2% for inter- and intraday precisi

249 ns were 7.1 ng/mL (coefficient of variation [CV], 73.9%) for lotion, 3.5 ng/mL (CV, 70.9%) for aeroso

250 ention time (<0.3% coefficient of variation, CV) and protein quantification (<7.5% CV) using data fro

251 The median coefficient variations (CV%) of absolute spectra ion intensities in both labs we

252 zed spatial fibre modes, cylindrical vector (CV) beams and helical phase front optical vortex (OV) be

253 ates displayed higher conduction velocities (CVs) and improved electrophysiological properties.

254 circuit dimensions and conduction velocity (CV) across a wide range of both stable and unstable VTs

255 aracterizing myocardial conduction velocity (CV) in patients with ischemic cardiomyopathy (ICM) and v

256 Conduction velocity (CV) is an important property that contributes to the arr

257 VERTIS CV (Evaluation of Ertugliflozin Efficacy and Safety Card

258 tericidal polymer containing crystal violet (CV) and thiolated gold nanocluster ([Au(25)(Cys)(18)]) a

259 ral complexity through compensation voltage (CV) switching using high-field asymmetric waveform ion m

260 r constant current (CC) or constant voltage (CV) charging mode with pH ranged from 5 to 9 in the feed

261 10 s by multicomponent cyclic voltammetric (CV) analysis on unmodified glassy carbon under ubiquitou

262 nsor has been studied by cyclic voltammetry (CV) and chronoamperometry (CA) in phosphate buffer (Argo

263 tric techniques, such as cyclic voltammetry (CV) and differential pulse voltammetry (DPV) are used ra

264 Cyclic Voltammetry (CV) and Differential Pulse Voltammetry (DPV) techniques

265 The cyclic voltammetry (CV) and electrochemical impedance spectroscopy (EIS) sho

266 step was accompanied by cyclic voltammetry (CV) and scanning electron microscopy (SEM).

267 udies; conducted through cyclic voltammetry (CV) and square wave voltammetry (SWV) measurements.

268 complex stoichiometry in cyclic voltammetry (CV) at macroelectrodes.

269 Cyclic voltammetry (CV) scans under synchronous optical readout were perform

270 adation determined using cyclic voltammetry (CV) with the redox indicator [Fe(CN)(6)](3-/4-).

271 frared spectrum (FT-IR), cyclic voltammetry (CV), and electrochemical impedance spectroscopy (EIS) we

272 As verified with STM, cyclic voltammetry (CV), and temperature-programmed desorption (TPD) measure

273 their redox potential by cyclic voltammetry (CV), antioxidant capacity (ABTS radical cation decoloriz

274 mical techniques such as Cyclic Voltammetry (CV), Electrochemical Impedance Spectroscopy (EIS) and Di

275 tion, UV/Vis absorption, cyclic voltammetry (CV), electron paramagnetic resonance (EPR) spectroscopy,

276 lent 3 was explored with cyclic voltammetry (CV), zero-field (57)Fe Mossbauer, near-infrared (NIR) sp

277 e spectroscopy (EIS) and cyclic voltammetry (CV).

278 sensor was studied using cyclic voltammetry (CV).

279 r was investigated using cyclic voltammetry (CV).

280 ve voltammetry (SWV) and cyclic voltammetry (CV).

281 rential pulse (DPV), and cyclic voltammetry (CV).

282 microscopy (FE-SEM) and cyclic voltammetry (CV).

283 q11.2DS show alterations in cortical volume (CV), cortical thickness (CT) and surface area (SA).

284 ntral subfield thickness (CST), cube volume (CV), and cube average thickness (CAT) were collected fro

285 The primary outcome for both analyses was CV hospitalization following prescription of clarithromy

286 ypertension is independently associated with CV event-free survival among individuals undergoing eval

287 cilizumab administration was associated with CV events, where the risk increased 1.7-fold with each 1

288 idated MS2 RNA was exclusively detected with CV-SAXS and compared with a structure derived from asymm

289 was shown that the polymer encapsulated with CV do not have photobactericidal activity under white li

290 .24, p=0.015) when compared to patients with CV > 44.2% and TTR > 40% (high intra-patient variability

291 Patients with CV > 44.2% and TTR < 40% (high intra-patient variability

292 P = 0.015) when compared with patients with CV >44.2% and TTR >=40% (high intrapatient variability a

293 Patients with CV >44.2% and TTR <40% (high intrapatient variability an

294 r patients had similar risk to patients with CV < 44.2% (lower intra-patient variability).

295 r patients had similar risk to patients with CV <44.2% (lower intrapatient variability).

296 aseline grade 3 DD was a predictor of 1-year CV death/rehospitalization (hazard ratio: 2.73; 95% conf

297 =1 grade of DD/grade 1 DD had reduced 1-year CV death/rehospitalization (p < 0.001) and increased 2-y

298 de 1 DD at 30 days was protective for 1-year CV death/rehospitalizations (hazard ratio: 0.39; 95% con

299 ardiac troponin T or NT-proBNP had a 10-year CV incidence rate of 11.0% and 4.6%, with a 10-year numb

300 without an elevated biomarker had a 10-year CV incidence rate of 15.1% and 7.9%, with a 10-year numb